Alzheimer's and Dementia: Translational Research and Clinical Interventions

ESCI-ISI SCOPUS (2015-2025)

  2352-8737

 

  Mỹ

 

Cơ quản chủ quản:  WILEY , John Wiley & Sons Inc.

Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)

Phân tích ảnh hưởng

Các bài báo tiêu biểu

Inflammation as a central mechanism in Alzheimer's disease
Tập 4 Số 1 - Trang 575-590 - 2018
Jefferson W. Kinney, Shane M. Bemiller, Andrew S. Murtishaw, Amanda M. Leisgang, Arnold Salazar, Bruce T. Lamb
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the brain's resident macrophages (micro... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2018
Tập 4 Số 1 - Trang 195-214 - 2018
Jeffrey L. Cummings, Garam Lee, Aaron Ritter, Kate Zhong
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in... hiện toàn bộ
Alzheimer's disease drug development pipeline: 2017
Tập 3 Số 3 - Trang 367-384 - 2017
Jeffrey L. Cummings, Garam Lee, Travis Mortsdorf, Aaron Ritter, Kate Zhong
AbstractIntroductionThere is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in clinicaltrials.gov for phase I, phase II, and phase III, accessed 1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline, of which 25 agents are... hiện toàn bộ
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
Tập 3 Số 3 - Trang 291-300 - 2017
Michael J. Wheeler, Paddy C. Dempsey, Megan S. Grace, Kathryn A. Ellis, Paul A. Gardiner, Daniel J. Green, David W. Dunstan
AbstractCognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been linked to poor glycemic control and... hiện toàn bộ
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Tập 4 - Trang 444-449 - 2018
Rebecca E. Amariglio, Rachel F. Buckley, Elizabeth C. Mormino, Gad A. Marshall, Keith A. Johnson, Dorene M. Rentz, Reisa A. Sperling
AbstractIntroductionTo investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden.MethodsTwo hundred seventy‐nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community‐dwe... hiện toàn bộ
Accelerating drug development for Alzheimer's disease through the use of data standards
Tập 3 - Trang 273-283 - 2017
Jon Neville, Steve Kopko, Klaus Romero, Brian Corrigan, Bob Stafford, Elizabeth LeRoy, Steve Broadbent, Martin Cisneroz, Ethan Wilson, Eric Reiman, Hugo Vanderstichele, Stephen P. Arnerić, Diane Stephenson
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integration of clinical data sets and represent the essential foundation for... hiện toàn bộ
A blood‐based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
Tập 5 - Trang 953-963 - 2019
Gene L. Bowman, Hiroko H. Dodge, Sophie Guyonnet, Nina Zhou, Juliana Donohue, Aline Bichsel, Jeroen Schmitt, Claudie Hooper, Tamas Bartfai, Sandrine Andrieu, Bruno Vellas
AbstractIntroductionMultinutrient approaches may produce more robust effects on brain health through interactive qualities. We hypothesized that a blood‐based nutritional risk index (NRI) including three biomarkers of diet quality can explain cognitive trajectories in the multidomain Alzheimer prevention trial (MAPT) over 3‐years.MethodsThe NRI included erythrocyte n‐3 polyunsaturated fatty acids ... hiện toàn bộ
The My Active and Healthy Aging (My‐AHA) ICT platform to detect and prevent frailty in older adults: Randomized control trial design and protocol
Tập 4 - Trang 252-262 - 2018
Mathew J. Summers, Innocenzo Rainero, Alessandro E. Vercelli, Georg Aumayr, Helios de Rosario, Michaela Mönter, Ryuta Kawashima
AbstractIntroductionFrailty increases the risk of poor health outcomes, disability, hospitalization, and death in older adults and affects 7%–12% of the aging population. Secondary impacts of frailty on psychological health and socialization are significant negative contributors to poor outcomes for frail older adults.MethodThe My Active and Healthy Aging (My‐AHA) consortium has developed an infor... hiện toàn bộ
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
Tập 4 - Trang 283-287 - 2018
Silvia Rios-Romenets, Natalia Acosta-Baena, Liliana Lopez, Lucia Madrigal-Zapata, Helen Street, Laura Jakimovich, Jessica B. Langbaum, William Cho, Eric M. Reiman, Pierre N. Tariot, Francisco Lopera
AbstractIntroductionThe Alzheimer's Prevention Initiative Colombia Trial is a collaborative project involving the Neurosciences Group of Antioquia, Genentech/Roche, and the Banner Alzheimer's Institute, studying whether crenezumab can delay or prevent the clinical onset of Alzheimer's disease in cognitively unimpaired individuals who carry the PSEN1 E280A mutation. In an effort to optimize partici... hiện toàn bộ
Poor cerebrovascular function is an early marker of cognitive decline in healthy postmenopausal women
Tập 2 - Trang 162-168 - 2016
Rachel H.X. Wong, Hamish M. Evans, Peter R.C. Howe
AbstractIntroductionImpairment of cerebrovascular function becomes evident after menopause. No study has yet explored relationships between deficits in cerebrovascular function, cognitive performance, and mood in postmenopausal women.MethodCerebrovascular function was assessed in 80 healthy postmenopausal women by monitoring blood flow velocity (BFV) in the middle and posterior cerebral arteries u... hiện toàn bộ